TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| WellPoint Fires Back at Obama The war of words between the Obama administration and WellPoint escalated over the weekend, as the president made comments seen as critical of the insurer, and WellPoint's chief executive shot back in defense. online.wsj.com |
Biomarker Diagnostics Drive Personalized Medicine but Path to Market Still Rife With Hurdles Rod Raynovich submits:Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago, with about 15,000 attendees, there were ten "Breakout Sessions on Biomarkers (BM)" encompassing Intellectual Property, commercialization, reimbursement, drug development and diagnostics. This explosive new technology niche is a nascent paradigm for exploiting breakthroughs in the molecular basis of disease and more targeted medicine, and assumes a need for co-development of diagnostics and drugs. Genomics transformed biology and now we are seeing the impact on drug development and personalized diagnostic services with a focus on cancer and cardiovascular diseases.Complete Story » seekingalpha.com |
Dendreon Continues to Suffer From Misleading Reports Wall Street Cheat Sheet submits: By Elliot TurnerIn afterhours trading Wednesday, shares of Dendreon (DNDN) went on a roller coaster ride that saw prices drop from its closing price of $33.39 to below $30 in a matter of minutes. Within the next half hour the stock once again reached its closing price and proceeded to trade all the way up to $33.89, up $0.50 cents from the day’s close. On what other stock would you see the following two articles posted within minutes of each other? The first sent Dendreon on its wild plunge:Complete Story » seekingalpha.com |
Fergie at the Avon Walk for Breast Cancer - Video Award-Winning Singer Fergie Joins Thousands of Participants at the Avon Walk for Breast Cancer Santa Barbara -- Event Raises More than $6.4 Million feedproxy.google.com |
Generex 's Acquisition Into the Direct to Consumer Diabetes Market Provides Synergistic Value R.J Steffens submits:Generex Biotechnology's (GNBT) shareholders have read a lot of corporate news as of late, from a management change to the signing of sales and distribution agreements. Last week, Ms. Gluskin was replaced as CEO by VP and General Counsel Mark Fletcher. Generex has a loyal base of shareholders, due to the leadership provided by Ms. Gluskin and Ms. Perri, who have brought the company very close to achieving the success they dreamed of, and Monday another step appears to have been taken to strengthen the foundation of the corporation. Undoubtedly, this could not have come together without the work of the former CEO, since the management change only occurred last week. She should be recognized for her effort, and I begin by doing so. Generex announced Monday morning that they have reached an agreement to acquire a 51% ownership stake in Global Medical Direct LLC. This news comes after a weekend full of wild speculation, due to an after hours press release by Generex alerting investors that they would be making a key material announcement before yesterday morning's market opening. Many shareholders were guessing partnership news could be brewing between Generex's oncology subsidiary and Pfizer (PFE) for the small biotechnology's immunotherapeutic peptide vaccine that has drawn attention due to the very promising interim Phase II results for early stage breast cancer patients that were last updated at ASCO in June. While news of a partnership nature for Generex waits for a later date, I feel Monday's news, once digested, is a surprisingly smart strategic development that brings synergistic strength most often seen in much larger companies completing channel distribution deals to support product growth.Complete Story » seekingalpha.com |